Hospital
Lexington County Health Services District INC
Lexington County Health Services District INC was paid $19.28M by Medicaid between Jan 2018 and Jan 2021, across 348 billing codes. Its largest line is 36415, Collection of venous blood by venipuncture — 14% of everything it billed.
33Billing provider infoLEXINGTON COUNTY HEALTH SERVICES DISTRICT INC
WEST COLUMBIA, SC 29169
WEST COLUMBIA, SC 29169
33aNPI1356366314assigned 07/12/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$19.28M
24GClaims963,961
24DCodes billed348
24AFirst – last monthJan 2018 – Jan 2021
Compared with peers
Next to other General Acute Care Hospital providers in South Carolina
Rank by total paid#19 of 115
Median peer was paid$2.47M
This provider vs. median7.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official SARVIS, MELINDA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 291,039 | $5.93M | |
| 2019 | 316,711 | $6.45M | |
| 2020 | 328,050 | $6.29M | |
| 2021 | 28,161 | $598K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 36415 | Collection of venous blood by venipuncture | 14% | 37,133 | 25,201 | $2.72M |
| J7030 | Infusion, normal saline solution , 1000 cc | 12% | 11,815 | 9,084 | $2.33M |
| 80053 | Comprehensive metabolic panel | 8.3% | 39,987 | 33,757 | $1.61M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 4.5% | 20,394 | 18,697 | $871K |
| J7050 | Infusion, normal saline solution, 250 cc | 4.4% | 8,912 | 4,444 | $845K |
| 86900 | 3.8% | 6,298 | 5,651 | $737K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 3.3% | 4,154 | 3,532 | $634K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.5% | 19,014 | 14,109 | $477K |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 2.3% | 552 | 470 | $442K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.2% | 13,362 | 12,638 | $415K |
| 81001 | 1.9% | 27,676 | 23,976 | $361K | |
| 84439 | 1.6% | 10,392 | 9,854 | $299K |
336 more codes
| 99284 | Emergency room visit (serious) | 1.4% | 22,047 | $269K |
| 87480 | 1.3% | 3,139 | $242K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.2% | 18,194 | $225K |
| 86703 | 1.2% | 7,087 | $225K | |
| 86695 | 1.1% | 1,178 | $218K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.1% | 7,392 | $215K |
| 82565 | 1.0% | 1,073 | $196K | |
| 87081 | <1% | 11,995 | $189K | |
| 87077 | <1% | 7,732 | $185K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,639 | $154K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,806 | $151K |
| 71250 | <1% | 854 | $150K | |
| 93971 | <1% | 993 | $141K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,857 | $140K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 484 | $133K |
| 83021 | <1% | 1,080 | $126K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 4,212 | $124K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,491 | $122K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,439 | $121K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,640 | $114K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 6,157 | $112K |
| 82962 | <1% | 5,160 | $103K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 10,232 | $102K |
| 99285 | Emergency room visit (most serious) | <1% | 15,341 | $99K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 3,693 | $97K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 575 | $95K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 6,916 | $90K |
| 84702 | <1% | 6,268 | $90K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,514 | $89K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 4,597 | $86K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 924 | $83K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 2,460 | $82K |
| 71045 | Radiologic examination, chest; single view | <1% | 11,271 | $71K |
| 80061 | Lipid panel | <1% | 8,737 | $70K |
| 72141 | <1% | 180 | $69K | |
| 82950 | <1% | 3,599 | $69K | |
| 87210 | <1% | 1,518 | $65K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 216 | $65K |
| 77336 | <1% | 533 | $62K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,636 | $57K |
| 87070 | <1% | 1,890 | $57K | |
| 73030 | <1% | 1,070 | $56K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 45,488 | $55K |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 677 | $54K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 17,800 | $53K |
| 82607 | <1% | 2,166 | $49K | |
| 77062 | <1% | 258 | $49K | |
| 73610 | <1% | 801 | $48K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,589 | $48K |
| 77300 | <1% | 61 | $46K | |
| 93970 | <1% | 384 | $45K | |
| 77066 | Tomosynthesis, mammo | <1% | 819 | $45K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 449 | $43K |
| 85027 | <1% | 17,683 | $42K | |
| 73630 | <1% | 1,030 | $42K | |
| 72100 | <1% | 1,435 | $42K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 13,586 | $41K |
| 76642 | <1% | 1,144 | $41K | |
| 86038 | <1% | 1,441 | $41K | |
| 72040 | <1% | 653 | $41K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 398 | $38K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 19,053 | $37K |
| 73564 | <1% | 1,204 | $35K | |
| G0378 | Hospital observation service, per hour | <1% | 18,275 | $34K |
| 73130 | <1% | 743 | $33K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 81 | $33K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 481 | $32K |
| 80076 | <1% | 2,366 | $31K | |
| 81025 | <1% | 11,904 | $31K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,374 | $30K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,212 | $30K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,130 | $29K |
| 81511 | <1% | 339 | $28K | |
| 73110 | <1% | 413 | $28K | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 1,103 | $26K |
| 76830 | Ultrasound, transvaginal | <1% | 740 | $23K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,387 | $22K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 995 | $21K |
| 82728 | <1% | 2,124 | $21K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,329 | $21K |
| 70486 | <1% | 422 | $21K | |
| 84112 | <1% | 248 | $21K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 8,998 | $20K |
| 74018 | <1% | 820 | $18K | |
| 78306 | <1% | 37 | $17K | |
| 86140 | <1% | 3,430 | $17K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,959 | $17K |
| C1729 | Catheter, drainage | <1% | 124 | $17K |
| J1815 | Injection, insulin, per 5 units | <1% | 1,949 | $16K |
| 73502 | <1% | 755 | $16K | |
| 83735 | <1% | 6,415 | $16K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 932 | $15K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 7,161 | $15K |
| 85610 | <1% | 12,580 | $15K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 9,360 | $15K |
| 88142 | <1% | 1,262 | $15K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 199 | $14K |
| 83001 | <1% | 481 | $14K | |
| 86225 | <1% | 875 | $14K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 14,531 | $14K |
| 86850 | <1% | 5,307 | $14K | |
| 83690 | <1% | 11,218 | $14K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 8,141 | $14K |
| 76536 | <1% | 190 | $13K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 6,124 | $13K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 17,498 | $12K |
| 88304 | <1% | 1,257 | $12K | |
| 82550 | <1% | 1,539 | $12K | |
| 83540 | <1% | 2,453 | $11K | |
| 84550 | <1% | 1,144 | $11K | |
| 10060 | <1% | 46 | $10K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,364 | $10K |
| 76770 | <1% | 272 | $9K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 289 | $9K |
| 87045 | <1% | 177 | $9K | |
| 84146 | <1% | 387 | $9K | |
| 87507 | <1% | 42 | $9K | |
| 82731 | <1% | 102 | $9K | |
| 82570 | <1% | 1,907 | $9K | |
| 96376 | <1% | 7,399 | $8K | |
| 97161 | <1% | 1,433 | $8K | |
| 86704 | <1% | 2,116 | $8K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,329 | $8K |
| 85378 | <1% | 3,364 | $8K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 11,391 | $8K |
| J2704 | Injection, propofol, 10 mg | <1% | 5,825 | $7K |
| 76801 | <1% | 1,927 | $7K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 439 | $7K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 3,179 | $7K |
| 73080 | <1% | 103 | $7K | |
| 77412 | <1% | 165 | $7K | |
| 82043 | <1% | 912 | $7K | |
| 83880 | <1% | 4,835 | $7K | |
| 77065 | Tomosynthesis, mammo | <1% | 280 | $6K |
| C1769 | Guide wire | <1% | 1,425 | $6K |
| 77334 | <1% | 17 | $6K | |
| 84484 | <1% | 10,064 | $6K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 9,573 | $6K |
| 86706 | <1% | 2,315 | $6K | |
| 70491 | <1% | 41 | $6K | |
| 73560 | <1% | 182 | $5K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,141 | $5K |
| 82784 | <1% | 100 | $5K | |
| 87205 | <1% | 1,958 | $5K | |
| 73090 | <1% | 122 | $5K | |
| 88307 | <1% | 458 | $5K | |
| 83655 | <1% | 429 | $5K | |
| 84155 | <1% | 333 | $4K | |
| 86235 | <1% | 1,094 | $4K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,096 | $4K |
| 82746 | <1% | 775 | $4K | |
| 93226 | <1% | 13 | $4K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 156 | $4K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,595 | $4K |
| 87040 | <1% | 2,649 | $4K | |
| 70496 | <1% | 13 | $4K | |
| 93225 | <1% | 101 | $4K | |
| 74022 | <1% | 468 | $4K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 68 | $4K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,732 | $4K |
| 82951 | <1% | 671 | $3K | |
| 87340 | <1% | 6,853 | $3K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,721 | $3K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 913 | $3K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,802 | $3K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 155 | $3K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 50 | $3K |
| 86160 | <1% | 622 | $3K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,827 | $3K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 324 | $3K |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 21 | $3K |
| 84403 | <1% | 377 | $3K | |
| 88342 | <1% | 859 | $3K | |
| 82805 | <1% | 793 | $3K | |
| 85730 | <1% | 10,329 | $3K | |
| 84145 | <1% | 785 | $3K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,056 | $3K |
| 87486 | <1% | 165 | $2K | |
| 82785 | <1% | 71 | $2K | |
| 82670 | <1% | 37 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,997 | $2K |
| 86769 | <1% | 34 | $2K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 5,581 | $2K |
| 12001 | <1% | 27 | $2K | |
| 97165 | <1% | 620 | $2K | |
| 85652 | <1% | 3,123 | $2K | |
| 85049 | <1% | 13 | $2K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,714 | $2K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,040 | $2K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,150 | $2K |
| 86780 | <1% | 6,701 | $2K | |
| 83516 | <1% | 61 | $2K | |
| 85613 | <1% | 42 | $2K | |
| 87186 | <1% | 5,770 | $2K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 714 | $2K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 336 | $2K |
| 86803 | <1% | 7,185 | $2K | |
| 73590 | <1% | 123 | $2K | |
| 84153 | <1% | 187 | $2K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,990 | $2K |
| 84156 | <1% | 1,576 | $2K | |
| 87632 | <1% | 87 | $2K | |
| 72070 | <1% | 67 | $2K | |
| 80164 | <1% | 325 | $2K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,486 | $2K |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,356 | $2K |
| 93017 | <1% | 108 | $2K | |
| Q9954 | Oral magnetic resonance contrast agent, per 100 ml | <1% | 1,247 | $1K |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 38 | $1K |
| 77061 | <1% | 14 | $1K | |
| 83605 | <1% | 2,199 | $1K | |
| 82947 | <1% | 105 | $1K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 831 | $1K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 521 | $1K |
| J7510 | Prednisolone oral, per 5 mg | <1% | 57 | $1K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,487 | $1K |
| 83550 | <1% | 1,664 | $1K | |
| 82525 | <1% | 215 | $1K | |
| 87631 | <1% | 116 | $1K | |
| 73140 | <1% | 26 | $1K | |
| 83520 | <1% | 40 | $1K | |
| 86431 | <1% | 998 | $1K | |
| 36430 | <1% | 382 | $1K | |
| 97116 | <1% | 730 | $1K | |
| 86200 | <1% | 515 | $952.88 | |
| 82533 | <1% | 60 | $918.14 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,158 | $845.46 |
| 87807 | <1% | 89 | $822.47 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 1,042 | $821.75 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 766 | $789.42 |
| Q9961 | High osmolar contrast material, 250-299 mg/ml iodine concentration, per ml | <1% | 159 | $779.86 |
| 97162 | <1% | 28 | $678.07 | |
| 84270 | <1% | 91 | $653.14 | |
| 86762 | <1% | 3,863 | $645.44 | |
| 86901 | <1% | 6,299 | $629.39 | |
| 82150 | <1% | 191 | $594.97 | |
| 82553 | <1% | 23 | $559.47 | |
| 84481 | <1% | 707 | $549.10 | |
| 73552 | <1% | 18 | $520.66 | |
| 83970 | <1% | 149 | $478.58 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,074 | $466.24 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 937 | $429.35 |
| 85660 | <1% | 1,002 | $415.60 | |
| 83615 | <1% | 377 | $415.54 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 296 | $410.52 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 13,354 | $393.25 |
| 83013 | <1% | 13 | $365.45 | |
| A9270 | Non-covered item or service | <1% | 95 | $364.77 |
| 83525 | <1% | 164 | $351.88 | |
| 84144 | <1% | 12 | $351.45 | |
| 82103 | <1% | 12 | $339.91 | |
| 87493 | <1% | 25 | $327.52 | |
| 87641 | <1% | 27 | $223.68 | |
| 86787 | <1% | 1,845 | $222.02 | |
| 82747 | <1% | 716 | $183.80 | |
| 84132 | <1% | 187 | $172.07 | |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 1,195 | $162.82 |
| 82140 | <1% | 113 | $155.16 | |
| 85045 | <1% | 1,108 | $133.71 | |
| 87075 | <1% | 706 | $129.76 | |
| 86141 | <1% | 69 | $127.47 | |
| 86709 | <1% | 2,056 | $121.91 | |
| 85014 | <1% | 256 | $119.22 | |
| 86039 | <1% | 1,226 | $104.04 | |
| 86376 | <1% | 70 | $77.39 | |
| 86480 | <1% | 49 | $76.49 | |
| 90715 | <1% | 700 | $62.02 | |
| 87522 | Neg quan hep c or qual rna | <1% | 12 | $57.97 |
| 83883 | <1% | 14 | $54.50 | |
| 81015 | <1% | 49 | $51.73 | |
| 88173 | <1% | 113 | $42.01 | |
| 82105 | <1% | 12 | $40.77 | |
| 83090 | <1% | 26 | $38.60 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 118 | $38.08 |
| 86777 | <1% | 113 | $37.13 | |
| 84100 | <1% | 1,070 | $33.23 | |
| 86256 | <1% | 80 | $32.54 | |
| 84425 | <1% | 351 | $28.74 | |
| 82247 | <1% | 20 | $23.98 | |
| 87899 | <1% | 58 | $18.62 | |
| 86923 | <1% | 417 | $7.85 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 319 | $7.00 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | 0% | 449 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 762 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 249 | $0.00 |
| 84630 | 0% | 165 | $0.00 | |
| 86696 | 0% | 1,171 | $0.00 | |
| 84165 | 0% | 468 | $0.00 | |
| 87660 | 0% | 3,146 | $0.00 | |
| 77012 | 0% | 16 | $0.00 | |
| 84597 | 0% | 130 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 113 | $0.00 |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | 0% | 116 | $0.00 |
| 86147 | 0% | 14 | $0.00 | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 0% | 32 | $0.00 |
| 86334 | 0% | 40 | $0.00 | |
| 84460 | 0% | 27 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 18 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 135 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 117 | $0.00 |
| 96367 | 0% | 71 | $0.00 | |
| J2300 | Injection, nalbuphine hydrochloride, per 10 mg | 0% | 127 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 28 | $0.00 |
| 10005 | 0% | 16 | $0.00 | |
| J1245 | Injection, dipyridamole, per 10 mg | 0% | 21 | $0.00 |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 0% | 94 | $0.00 |
| 93458 | 0% | 97 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 292 | $0.00 |
| 97535 | Self-care/home management training, each 15 minutes | 0% | 252 | $0.00 |
| 87510 | 0% | 3,139 | $0.00 | |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 17 | $0.00 |
| 88341 | 0% | 79 | $0.00 | |
| 82952 | 0% | 665 | $0.00 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 92 | $0.00 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 0% | 171 | $0.00 |
| 86778 | 0% | 113 | $0.00 | |
| 87046 | 0% | 165 | $0.00 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 14 | $0.00 |
| 20610 | 0% | 26 | $0.00 | |
| 90686 | 0% | 53 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 42 | $0.00 |
| 88311 | 0% | 26 | $0.00 | |
| 83921 | 0% | 73 | $0.00 | |
| 86800 | 0% | 66 | $0.00 | |
| 83002 | 0% | 66 | $0.00 | |
| 85018 | 0% | 187 | $0.00 | |
| 74021 | 0% | 36 | $0.00 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 67 | $0.00 |
| 84480 | 0% | 14 | $0.00 | |
| 70498 | 0% | 14 | $0.00 | |
| 87581 | 0% | 165 | $0.00 | |
| G0379 | Direct admission of patient for hospital observation care | 0% | 16 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 22 | $0.00 |
| J1335 | Injection, ertapenem sodium, 500 mg | 0% | 46 | $0.00 |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 46 | $0.00 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSARVIS, MELINDA (EXECUTIVE VICE PRESIDENT)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.